OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.
Keyword(s):
Phase Ii
◽
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 868-868
◽
Keyword(s):
2015 ◽
Vol 33
(15_suppl)
◽
pp. 616-616
Keyword(s):
2010 ◽
Vol 8
(3)
◽
pp. 203-204
Keyword(s):